Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Jiangsu Atom Bio Begins Global Phase IIb/III Trial of Gout Treatment

publication date: Oct 9, 2023

Jiangsu Atom Bioscience has dosed the first patient in a Phase IIb/III trial of its lead drug, ABP-671, a novel orally administered URAT1 inhibitor aimed at treating chronic gout. By reducing the reabsorption of uric acid in the kidneys, ABP-671 increases the excretion of uric acid. The multicenter, randomized, double-blind trial will enroll 580 patients globally, including the US. Part I will evaluate the safety and efficacy of ABP-671 at different doses with results available by the end of 2024. Part II will be a confirmatory study. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital